SCHEDULE 13G/A: Two Seas Capital Discloses 8% Passive Stake in Adaptimmune Therapeutics PLC

Two Seas Capital LP, along with its general partner and chief investment officer, has reported a passive 8% beneficial ownership stake in Adaptimmune Therapeutics PLC.

Summary

• Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The filing discloses beneficial ownership of 123,178,110 Ordinary Shares, par value GBP 0.001 per share, of Adaptimmune Therapeutics PLC.
• This aggregate amount represents 8.0% of the outstanding class of securities.
• The shares are held by Two Seas Global (Master) Fund LP, for which Two Seas Capital LP serves as investment adviser.
• The Reporting Persons, including Sina Toussi as chief investment officer of Two Seas Capital LP and managing member of Two Seas Capital GP LLC, have sole voting and sole dispositive power over these shares.
• The percentage of class is calculated based on 1,543,391,646 Ordinary Shares outstanding as of March 21, 2025, as reported in Adaptimmune's Form 10-K filed on March 24, 2025.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership filing (Schedule 13G) indicating a passive stake. It contains no operational or financial performance data, nor does it suggest any activist intent, leading to a neutral sentiment.

Positives

• The disclosure of an 8% passive stake by Two Seas Capital indicates a significant institutional investment in Adaptimmune Therapeutics PLC, potentially signaling confidence in the company's long-term prospects.
• The certification explicitly states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a stable, passive large shareholder.

Risks

• The document does not detail specific risks related to Adaptimmune Therapeutics PLC's operations or financial health, as it is a beneficial ownership filing. It primarily addresses the nature of the reported ownership.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Adaptimmune Therapeutics PLC's future operations or financial performance. It solely reports a passive beneficial ownership stake.

Industry Context

This filing is a standard disclosure of a significant passive ownership stake by an investment firm in a publicly traded biotechnology company. It does not provide insights into broader industry trends or competitive dynamics, but rather reflects an investment decision within the sector.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially provide a degree of stability to the shareholder base.
• Management: Awareness of a large passive shareholder may influence strategic considerations, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Adaptimmune Therapeutics PLC, Two Seas Capital, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investment, Ordinary Shares, ADS, Passive Stake